...
首页> 外文期刊>Pharmacology & Pharmacy >The Impact of a Drug Safety Warning on Discussions between Doctors and Their Patients; the Case of Rosiglitazone
【24h】

The Impact of a Drug Safety Warning on Discussions between Doctors and Their Patients; the Case of Rosiglitazone

机译:药物安全警告对医生及其患者之间讨论的影响;罗格列酮案

获取原文
           

摘要

The goal of this study was to track the influence of a highly publicized report on discussions between doctors and their patients and prescribing decisions made in response to concerns about potential medication adverse side effects. This was a retrospective analysis of a primary care network’s electronic medical record database. From a diabetes registry of 12, 246 patients, 329 were identified as taking rosiglitazone prior to the June 14, 2007 release of an article in the New England Journal of Medicine; the article suggesting an increased risk of myocardial events. The entire content of all office visits, telephone messages, and medication lists for each patient were reviewed over a 2-year period subsequent to the article’s publication. Doctor/patient discussions regarding concerns for rosiglitazone were catalogued including the physician’s treatment recommendations. There were documented discussions on rosiglitazone’s potential adverse side effects for 64 patients; 19.5 percent of this population. All of the discussions occurred between June 15 and October 30, 2007. Of the entire group, 59.3 percent (N = 195) remained on rosiglitazone. For those advised to continue rosiglitazone, the provider indicated that he/she wanted more data before determining if the drug was not safe or discounted the validity of the safety concerns. For those advised to discontinue rosiglitazone, 112 (83.6 percent) were placed on pioglitazone. An article suggesting potential adverse effects of rosiglitazone resulted in a documented discussion in 19.5 percent of patients on this medication. These findings suggest an awareness of this publication by patients, presumably derived from media reports. However, an awareness of this concern did not result in a substantial change in practice.The majority of patients remained on rosiglitazone. The content of these discussions suggest that most physicians’ recommended waiting for more published data before considering a change. While many factors influence physician’s prescribing behavior, this study demonstrates how a highly publicized report influences the doctor/ patient dialogue.
机译:这项研究的目的是追踪一份高度公开的报告对医生及其患者之间的讨论的影响,并针对对潜在药物不良副作用的担忧做出处方决定。这是对基层医疗网络的电子病历数据库的回顾性分析。在2007年6月14日《新英格兰医学杂志》上发表的一篇文章中,根据12个糖尿病患者的246个病例中,有329人被确定服用罗格列酮。文章提示心肌事件的风险增加。在文章发表后的两年内,对每位患者的所有办公室拜访,电话留言和用药清单的全部内容进行了审查。列出了有关罗格列酮问题的医生/患​​者讨论,包括医生的治疗建议。关于罗格列酮对64位患者的潜在不良副作用的讨论已有文献记录;此人口的19.5%。所有讨论都在2007年6月15日至10月30日之间进行。在整个小组中,仍有59.3%(N = 195)仍在罗格列酮治疗上。对于被建议继续使用罗格列酮的患者,提供者表示,他/她需要更多数据,然后再确定该药物是否不安全或不考虑安全问题的有效性。对于那些建议停用罗格列酮的患者,吡格列酮放112片(83.6%)。一篇有关罗格列酮潜在不良反应的文章导致有19.5%的患者对此药进行了讨论。这些发现表明,患者对这种出版物的认识可能来自媒体报道。然而,意识到这种担忧并没有导致实践上的重大改变。大多数患者仍使用罗格列酮。这些讨论的内容表明,大多数医生建议在考虑更改之前,等待更多已发布的数据。尽管许多因素会影响医师的处方行为,但这项研究表明,受到高度宣传的报告如何影响医患对话。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号